RxDoctor Payments Data

Lorcan McKillop, PA

Physician Assistant · Long Island City, NYNPI 1326636622

Payments from drug & device makers

$14,028in general payments, 2019–2025

Across 555 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Mannkind Corporation$2K
  • Lilly USA, LLC$2K
  • Xeris Pharmaceuticals, Inc.$874
  • Abbott$750
  • Boehringer Ingelheim$732
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$14,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,028 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$37,156
Medicare patients
136
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin243$266,705
MounjaroTirzepatide215$257,585
OzempicSemaglutide177$240,422
TrulicityDulaglutide97$163,390
RybelsusSemaglutide80$130,555
FarxigaDapagliflozin Propanediol85$98,166
Tresiba Flextouch U-100Insulin Degludec82$39,957
Fiasp FlextouchInsulin Aspart (Niacinamide)34$23,775
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$17,078
JanuviaSitagliptin Phosphate11$16,073
Humalog Kwikpen U-100Insulin Lispro31$14,705
Gvoke Hypopen 2-PackGlucagon15$14,340
JanumetSitagliptin Phos/Metformin Hcl17$12,000
VascepaIcosapent Ethyl23$11,744
XyostedTestosterone Enanthate16$10,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,502$420,975312 claims
Novo NordiskOzempic, Rybelsus$2,588$370,976257 claims
Boehringer IngelheimJardiance$732$266,705243 claims
AstraZenecaFarxiga$80$98,16685 claims
Antares Pharma, Inc.Xyosted$306$10,82316 claims
AbbVieSynthroid, Armour Thyroid$384$7,03172 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$330$2,098155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Long Island City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →